Optimized and Genetically-Engineered TIL Therapies
Our optimized TIL therapies leverage our platform for TIL manufacturing, which has been designed to improve the scalability, logistics, and accessibility of TIL therapy. We are also developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform.
Optimized TIL
| Candidate | Indication | Discovery | IND-Enabling | Phase 1* | Phase 2/3 |
|---|---|---|---|---|---|
| ITIL-168 | Melanoma | ||||
| ITIL-168 | NSCLC | ||||
| ITIL-168 | HNSCC | ||||
| ITIL-168 | Cervical Cancer | ||||
| ITIL-168 | CSCC | ||||
CoStAR-TIL
| Candidate | Indication | Discovery | IND-Enabling | Phase 1 | Phase 2/3 |
|---|---|---|---|---|---|
| ITIL-306 | GYN, NSCLC, Other | ||||
*Initiation of Phase 2 trial based on strength of clinical results from a compassionate use program and subject to acceptance of IND by FDA
CSCC: cutaneous squamous cell carcinoma; NSCLC: non-small cell lung cancer; HNSCC: head and neck squamous cell carcinoma; GYN: gynecological malignancies